Growth Hormone Responsive Dermatosis in Dogs: Hair Loss Without Itch

By Emiel Maddens · Reviewed in consultation with licensed veterinary professionals · Updated August 2026 · 9 min read

What Is Growth Hormone Responsive Dermatosis in Dogs?

Growth hormone responsive dermatosis is a non-inflammatory, non-pruritic (non-itchy) hair loss disorder of young adult dogs in which the hair follicles arrest in a resting phase because of a relative deficiency of growth hormone, also called somatotropin. The skin itself is not inflamed, the dog is not itchy, and the animal remains otherwise healthy, which is precisely what separates this condition from the allergic and infectious causes of hair loss that owners encounter far more often.

The disorder was first characterized in the veterinary dermatology literature in the 1980s, when a subset of young adult dogs with symmetrical truncal alopecia were shown to have subnormal growth hormone response to stimulation testing and to regrow coat following exogenous somatotropin administration. Reported onset is typically between 1 and 5 years of age, with most cases presenting before age 3. Both sexes are affected, though several case series have reported a male predominance.

Breed clustering is striking. Plush-coated Nordic and spitz-type breeds account for the overwhelming majority of reported cases: Pomeranian, Chow Chow, Keeshond, Samoyed, Siberian Husky, Alaskan Malamute, along with the Miniature Poodle, Toy Poodle, and American Water Spaniel. This breed distribution overlaps almost perfectly with Alopecia X, which is a major reason the two conditions have become difficult to separate in modern practice.

It is worth stating clearly what this condition is not. It is not contagious, it is not painful, it does not shorten lifespan, and it is not caused by diet, grooming, or anything an owner did. The clinical burden is cosmetic plus the secondary consequence of having large areas of thin, unprotected skin.

What Causes Growth Hormone Responsive Dermatosis?

The proximate cause is insufficient growth hormone signaling at the level of the hair follicle. Growth hormone is secreted by the anterior pituitary gland and acts both directly and through insulin-like growth factor 1 (IGF-1) to drive the follicle from the resting phase, telogen, into the active growing phase, anagen. When that signal is blunted, follicles remain locked in telogen, the existing hairs eventually shed, and no new coat replaces them. Dermatopathologists describe the resulting picture as follicular atrophy with a predominance of telogen (kenogen) follicles and no meaningful inflammatory infiltrate.

Why the signal is blunted remains unresolved. Proposed mechanisms include a partial, adult-onset pituitary somatotroph deficiency, a defect in hypothalamic growth hormone releasing hormone, and, in a portion of cases, a broader disturbance in the adrenal steroid pathway rather than growth hormone itself. This last point matters: subsequent work has shown that many dogs historically diagnosed with growth hormone responsive dermatosis have elevated adrenal sex steroid intermediates on ACTH stimulation testing, and a substantial number are now reclassified as Alopecia X, a follicular dysplasia of plush-coated breeds. Some dermatologists consider the two entities points on a single spectrum of follicular growth arrest.

Genetics almost certainly plays a role given the breed clustering, though no single causative mutation has been confirmed. The pattern of affected breeds, nearly all double-coated with a dense secondary undercoat, suggests these coats are inherently more dependent on strong anagen induction signals and therefore less tolerant of a marginal hormonal deficit.

Importantly, castration or spaying resolves the alopecia in a meaningful proportion of these dogs, which further implicates sex steroid interplay with the growth hormone axis. For a fuller discussion of that overlap, see our guide on Sex Hormone Dermatosis in Dogs.

How Do Veterinarians Diagnose Growth Hormone Responsive Dermatosis?

Diagnosis is made by exclusion. There is no single confirmatory test available in routine practice, so the veterinarian's task is to systematically rule out every other cause of symmetrical, non-itchy alopecia before landing here.

The workup usually proceeds in this order. Step one is ruling out parasites and infection with deep skin scrapings for Demodex, cytology for bacteria and yeast, and a dermatophyte culture or PCR for ringworm. Step two is endocrine screening: a complete blood count, serum chemistry, urinalysis, total T4 with free T4 by equilibrium dialysis and TSH for hypothyroidism, and a low dose dexamethasone suppression test or ACTH stimulation test for hyperadrenocorticism. Step three, in intact animals, is evaluating sex hormone dermatosis, including abdominal ultrasound to look for a functional gonadal or adrenal tumor. Step four is a skin biopsy from a fully alopecic area, which shows the characteristic non-inflammatory follicular atrophy and, in many plush-coated breeds, excessive trichilemmal keratinization described as flame follicles.

Direct growth hormone measurement is impractical for most owners. Basal growth hormone concentrations fluctuate too much to interpret, so assessment requires a stimulation test using xylazine, clonidine, or ghrelin, and the assay must be validated for the dog. These tests are offered only through a small number of academic and referral laboratories. Serum IGF-1, which is more stable, is sometimes used as a surrogate marker, with low values supporting the diagnosis.

Here is how the main differentials separate on the exam table:

Signs and Symptoms to Watch For

The clinical picture is remarkably consistent, and recognizing the pattern early saves owners months of trial-and-error allergy treatment that was never going to work.

Coat changes come first. Owners typically report that the puppy coat never fully converted to an adult coat, or that after a normal shed the hair simply failed to grow back. The primary guard hairs are lost first, leaving a soft, woolly, puppy-like undercoat that gives the dog a fuzzy appearance. Over the following months that undercoat thins as well and true bald skin appears.

The distribution is the diagnostic clue. Hair loss is bilaterally symmetrical and concentrated on the neck, the collar region, the trunk, the caudal thighs, the perineum, and the tail. The tail often becomes almost completely bald, a presentation sometimes called rat tail. Critically, the head and the distal limbs are spared, which is the opposite of what you see in allergic dermatitis. Friction points such as the collar area and the sites where the dog lies down are often the first to go bald.

The skin changes follow the hair loss. Exposed skin becomes progressively hyperpigmented, shifting from pink to grey to a deep charcoal black. This is a normal response of unprotected skin to ultraviolet light and friction, not a sign of disease progression. The skin also becomes noticeably thin, soft, and hypotonic, and may feel cool to the touch because a lost coat means lost insulation.

What you should not see is itching, redness, pustules, scaling, crusting, odor, weight change, increased thirst, or lethargy. Any of those findings points somewhere else. Persistent scratching in a plush-coated dog with truncal alopecia usually means a secondary infection has developed on top of the underlying condition, which is discussed below. For a broader comparison of hair loss patterns, see Pattern Baldness in Dogs.

Treatment Options for Growth Hormone Responsive Dermatosis

Treatment decisions start with an honest conversation about goals. This is a cosmetic disorder in an otherwise healthy dog, and observation without intervention is a completely legitimate choice. Many board-certified dermatologists recommend it as the default, particularly for indoor dogs in temperate climates.

Neutering or spaying is the first-line intervention in intact dogs. Published case reports and clinical experience indicate that a meaningful proportion of affected intact animals regrow coat within 3 to 6 months of gonadectomy. It carries a well-understood risk profile, provides other health benefits, and avoids the hazards of hormone supplementation. Regrowth is not universal, and relapse after an initial response has been documented.

Exogenous growth hormone therapy is the historically definitive treatment and the one that gave the condition its name. Porcine or bovine somatotropin administered subcutaneously two to three times weekly for several weeks produces coat regrowth in responsive dogs, usually within 6 to 8 weeks. In practice it is rarely used. Veterinary-labeled product is largely unavailable, human recombinant growth hormone is expensive and prone to triggering antibody formation, and the therapy carries a real risk of inducing diabetes mellitus through insulin antagonism. Any dog receiving it requires serial blood glucose monitoring. Melatonin at commonly reported oral doses is a far safer first attempt and produces at least partial regrowth in a subset of cases, typically over 2 to 3 months.

The part that actually needs treating is the skin barrier. Alopecic, hyperpigmented skin has fewer hair follicles anchoring the surface lipid film, reduced mechanical protection, and altered surface humidity in the skin folds it creates. That environment favors overgrowth of Malassezia pachydermatis yeast and Staphylococcus pseudintermedius, both of which are normal residents that become opportunists when the barrier fails. A greasy feel, a musty odor, or new redness in bald areas is the signal.

Topical antimicrobial therapy targets that overgrowth directly at the skin surface without systemic exposure. Yeast Dermatitis Spray combines ketoconazole, an azole antifungal that blocks fungal ergosterol synthesis and destabilizes the yeast cell membrane, with chlorhexidine gluconate, a cationic biguanide that disrupts bacterial cell membranes and remains bound to the stratum corneum for hours after application. That dual action addresses the mixed yeast and bacterial overgrowth typical of chronically alopecic skin. It is an FDA-registered over-the-counter veterinary drug listed on DailyMed, not a cosmetic grooming product, and it is applied to affected areas rather than bathed off. For deeper reading on the underlying overgrowth, see Yeast Infections in Dogs: The Complete Guide to Malassezia Dermatitis and our clinical reference page on Yeast Infections in Dogs.

Prevention and Long-Term Management

There is no way to prevent growth hormone responsive dermatosis in a genetically predisposed dog. Management is therefore about protecting exposed skin and catching secondary problems early.

Sun protection is the highest-value intervention. Hyperpigmented skin has more melanin and therefore some intrinsic protection, but pink or lightly pigmented bald areas burn readily and chronic ultraviolet exposure is a documented risk factor for solar-induced skin damage and cutaneous neoplasia in dogs. Limit midday sun, use a lightweight breathable shirt for outdoor time, and apply a dog-safe, zinc-oxide-free and salicylate-free sunscreen to any exposed pink skin.

Thermal management matters more than owners expect. A dog that has lost most of its insulating undercoat loses body heat far faster than an intact-coated animal of the same breed. Provide a sweater or coat in cold weather, a padded bed off cold floors, and shortened outdoor time in winter.

Build a weekly skin check into your routine. Run your hands over the bald areas and look for redness, greasiness, odor, new bumps, or scaling. Because there is no coat in the way, these dogs are actually easier to monitor than most, and problems are caught weeks earlier than in a fully coated animal. Our Monthly Skin Check for Dogs guide walks through the process.

Do not over-bathe. Frequent shampooing of already thin, dry skin strips the remaining surface lipids and worsens barrier function. Bathe on a schedule your veterinarian sets based on whether secondary infection is present, and use targeted topical therapy between baths rather than more frequent full baths.

Recheck the endocrine picture annually. Because the differential list overlaps so heavily, a dog diagnosed by exclusion at age 2 may develop true hypothyroidism or hyperadrenocorticism at age 8. Annual bloodwork catches that shift. Any new sign of increased thirst, increased urination, weight change, or lethargy warrants a same-month recheck rather than waiting for the annual.

Frequently Asked Questions

Will my dog's hair grow back if he has growth hormone responsive dermatosis?

Sometimes, and it depends on the intervention. Neutering an intact dog produces coat regrowth in a meaningful share of cases within 3 to 6 months. Melatonin produces partial regrowth in a subset of dogs over 2 to 3 months. Exogenous growth hormone is the most reliable regrower, usually within 6 to 8 weeks, but it is rarely used because it can precipitate diabetes mellitus. Many dogs remain permanently bald over the trunk and live entirely normal lives.

Is growth hormone responsive dermatosis the same thing as Alopecia X?

They are increasingly treated as overlapping. Both affect plush-coated Nordic breeds between 1 and 5 years, both cause symmetrical truncal alopecia sparing the head and legs, and both show non-inflammatory follicular arrest on biopsy. The practical distinction is that many dogs once diagnosed with growth hormone responsive dermatosis show elevated adrenal sex steroid intermediates on ACTH stimulation testing and are now reclassified as Alopecia X. Some dermatologists consider them points on one spectrum of follicular growth arrest.

Does growth hormone responsive dermatosis make dogs itchy?

No. The defining feature is non-pruritic hair loss, meaning the dog does not scratch, lick, or chew at the affected skin. The alopecia results from follicles arresting in a resting phase, not from self-trauma. If your dog is itching, either the diagnosis is wrong, or a secondary yeast or bacterial infection has developed on the exposed skin, which is common and treatable.

Which dog breeds get growth hormone responsive dermatosis?

Plush-coated Nordic and spitz-type breeds dominate the reported cases: Pomeranian, Chow Chow, Keeshond, Samoyed, Siberian Husky, and Alaskan Malamute. The Miniature and Toy Poodle and the American Water Spaniel are also over-represented. These are all double-coated breeds with a dense secondary undercoat, which appears to depend more heavily on strong hormonal signals to re-enter the growth phase.

Is growth hormone responsive dermatosis dangerous or painful for my dog?

No. The condition is cosmetic and the dog is not in pain, not itchy, and not systemically ill. The two real risks are indirect. Bald skin has a weakened barrier and is prone to secondary yeast and bacterial overgrowth, and unpigmented bald skin is vulnerable to ultraviolet damage from sun exposure. Both are managed with topical antimicrobial care and simple sun protection.

Sources

1. Scott DW, Miller WH, Griffin CE. Endocrine and metabolic diseases. Muller and Kirk's Small Animal Dermatology. 7th ed. Elsevier; 2013:501-553.
2. Frank LA. Growth hormone-responsive alopecia in dogs. Journal of the American Veterinary Medical Association. 2005;226(9):1494-1497.
3. Frank LA, Hnilica KA, Oliver JW. Adrenal steroid hormone concentrations in dogs with hair cycle arrest (Alopecia X) before and during treatment with melatonin and mitotane. Veterinary Dermatology. 2004;15(5):278-284.
4. Cerundolo R, Lloyd DH, Persechino A, et al. Treatment of canine Alopecia X with trilostane. Veterinary Dermatology. 2004;15(5):285-293.
5. Paradis M. Melatonin therapy for canine alopecia. In: Bonagura JD, ed. Kirk's Current Veterinary Therapy XIII. WB Saunders; 2000:546-549.
6. Miller MA, Dunstan RW. Seasonal flank alopecia in boxers and Airedale terriers: 24 cases. Journal of the American Veterinary Medical Association. 1993;203(11):1567-1572.

Related Reading

• Alopecia X in Dogs: Black Skin Disease, Causes & Treatment
• Sex Hormone Dermatosis in Dogs: How Estrogen and Testosterone Affect Skin
• Pattern Baldness in Dogs: Normal Hair Loss Explained
• Dog Skin Biopsy Results: What They Mean

Emiel Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.

Veterinary review: All Vetified content is developed in consultation with licensed veterinary professionals and references peer-reviewed research published in journals including Veterinary Dermatology, JAVMA, and Journal of Small Animal Practice.